fenofibrate has been researched along with phenyl acetate in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Benéteau, N; Chapuis, V; Colpaert, FC; Dupont-Passelaigue, E; Junquéro, D; Lestienne, F; Patoiseau, JF; Rival, Y; Taillandier, T | 1 |
| Kallem, RR; Mullangi, R; Srinivas, NR; Trivedi, RK | 1 |
| Buckley, KA; Chan, BY; Dillon, JP; Fraser, WD; Gallagher, JA; Gartland, A; Wilson, PJ | 1 |
| Chew, GT; Sahebkar, A; Watts, GF | 1 |
| Hirschfield, GM; Webb, GJ | 1 |
| Bates, J; Breckenridge, DG; Hollenback, D; Kusam, S; Mahadevan, S; Marchand, B; Okesli-Armlovich, A; Olson, I; Seung, M; Toteva, M; Trevaskis, JL; Vijayakumar, A; Wang, T | 1 |
2 review(s) available for fenofibrate and phenyl acetate
| Article | Year |
|---|---|
New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.
Topics: Acetates; Animals; Atherosclerosis; Chalcones; Cholesterol, HDL; Dyslipidemias; Fatty Liver; Fenofibrate; Humans; Insulin Resistance; Lipoproteins, HDL; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptors; Propionates; Quinolines; Sulfonamides; Thiazoles; Triazoles; Triglycerides | 2014 |
Work in Progress: Drugs in Development.
Topics: Abatacept; Acetates; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Bezafibrate; CD40 Antigens; CD40 Ligand; Chalcones; Chemokine CX3CL1; Chenodeoxycholic Acid; Cholic Acids; Drug Development; Fenofibrate; Fibroblast Growth Factors; Humans; Hypolipidemic Agents; Immunosuppressive Agents; Janus Kinase Inhibitors; Liver Cirrhosis, Biliary; Methylamines; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR delta; PPAR gamma; Propionates; Pruritus; Receptors, Cytoplasmic and Nuclear; Receptors, G-Protein-Coupled; Thiazepines; Triazoles; Ustekinumab | 2018 |
4 other study(ies) available for fenofibrate and phenyl acetate
| Article | Year |
|---|---|
Cardiovascular drugs inhibit MMP-9 activity from human THP-1 macrophages.
Topics: Acetamides; Acetates; Anilides; Cardiovascular Agents; Cell Line; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Fenofibrate; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipoproteins, LDL; Macrophages; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Mevalonic Acid; Monocytes; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids; Tetradecanoylphorbol Acetate; Thiazolidinediones; Tissue Inhibitor of Metalloproteinase-1; Transcription Factors | 2004 |
Simultaneous determination of rosuvastatin and fenofibric acid in human plasma by LC-MS/MS with electrospray ionization: assay development, validation and application to a clinical study.
Topics: Acetates; Calibration; Carbamazepine; Chromatography; Chromatography, Ion Exchange; Chromatography, Liquid; Fenofibrate; Fluorobenzenes; Freezing; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Ions; Male; Mass Spectrometry; Models, Chemical; Pyrimidines; Quality Control; Reproducibility of Results; Rosuvastatin Calcium; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Sulfonamides; Temperature; Time Factors | 2005 |
PPAR agonists modulate human osteoclast formation and activity in vitro.
Topics: Acetates; Apoptosis; Bezafibrate; Bone Resorption; Butyrates; Cells, Cultured; Fenofibrate; Humans; Hypolipidemic Agents; Leukocytes, Mononuclear; Macrophage Colony-Stimulating Factor; Osteoclasts; Peroxisome Proliferator-Activated Receptors; Phenols; Phenoxyacetates; Phenylurea Compounds; RANK Ligand; RNA, Messenger; Thiazolidinediones; Transcription, Genetic | 2007 |
Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis.
Topics: Acetates; Acetyl-CoA Carboxylase; Animals; Fenofibrate; Humans; Hypertriglyceridemia; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; PPAR alpha; Rats; Triglycerides | 2022 |